Intensive chemotherapy in patients with generalized Burkitt's lymphoma
β Scribed by John L. Ziegler; Avrum Z. Bluming; Ian T. Magrath; Paul P. Carbone
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- French
- Weight
- 520 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The results of a clinical trial in patients with generalized Burkitt's lymphoma using either multiple doses of cyclophosphamide or a cyclic, sequential regimen employing cylophosphamide, vincristine, methotrexate, and cytosine arabinoside (TRIKE) are reported. Of 42 evaluable patients 24 received cyclophosphamide and 18 received TRIKE. No significant differences were encountered between either group with respect to remission induction, relapse rate or survival. Remission duration was significantly prolonged in the patients receiving cyclophosphamide, but this event has little effect on survival. Although intensive chemotherapy is probably necessary in patients with generalized Burkitt's lymphoma, other variables such as meningeal involvement and immunologic factors appear to affect relapse and survival.
π SIMILAR VOLUMES
## Abstract A microβassay colony inhibition (CI) test has been developed for studying cellβmediated reactions against lymphoblastoid target cells. The assay makes use of the ability of the target cells, but not the effector cells, to grow in discrete colonies in semiβsolid medium. Peripheral blood
## Abstract The clinical presentation, response to chemotherapy, relapse pattern and prognosis in Burkitt's lymphoma were evaluated in a prospective manner in 54 patients. Cyclophosphamide induced complete clinical remission in over 75% of the patients irrespective of stage of the disease. Longβter